argenx Acquires Forte Biosciences for $2.2B: What the All-Cash Deal Means for Biotech M&A

Event Analysis

argenx (Nasdaq/Euronext: ARGX), the Belgian-Dutch immunology company behind Vyvgart, has entered into a definitive agreement to acquire Forte Biosciences (Nasdaq: FBRX) for $77 per share in cash, implying an equity value of approximately $2.2 billion. According to official company communications and confirmed by Reuters and the Wall Street Journal, the deal is structured as a cash tender offer by a wholly owned argenx subsidiary, followed by a back-end merger at the same $77 price for any untendered shares. The transaction has been approved by both boards, carries no financing condition, and is expected to close in Q3 2026.

The strategic prize here is FB102, Forte's first-in-class anti-CD122 antibody, which showed positive Phase 1b results in vitiligo — announced July 9, 2026. argenx is paying an ~86% premium to Forte's VWAP since that data readout, and a ~41% premium to the last closing price prior to announcement, per the WSJ. Critically, argenx had already participated as a strategic investor in Forte's April 2026 $150 million equity offering at $26.27/share, signaling prior conviction well before signing. This is not opportunistic deal-making — it reflects a deliberate pipeline-building strategy in autoimmune disease.

This acquisition fits squarely into the broader pharma & fintech acquisition repricing dynamic reshaping mid-cap biotech. argenx has been actively broadening its external R&D footprint, including a separate $1.5 billion biobucks pact with Unnatural Products targeting so-called "undruggable" proteins. The Forte deal accelerates this global acquisition consolidation wave in immunology — where large commercial-stage players are paying premium multiples for Phase 1/2 assets rather than building internally. The all-cash, no-financing structure signals balance sheet strength and deal certainty, reducing closing risk materially.

For the broader ecosystem, a $2.2B all-cash deal on a Phase 1b asset sets a meaningful valuation benchmark for autoimmune biotechs. As detailed in our pharma M&A playbook, transactions of this scale and premium typically trigger speculative re-rating in peer names with comparable early-stage pipelines.

What This Means for Traders

For event-driven and acquisition arbitrage traders, FBRX becomes a near-pure merger arb play: the stock should trade just below $77, with the spread reflecting deal completion risk and time value to Q3 2026 close. Given the all-cash structure, no financing condition, and board approval on both sides, implied deal probability is high — though standard regulatory conditions and clinical execution risk for FB102 remain watch items. ARGX, as acquirer, faces the classic M&A tension: pipeline strengthening versus near-term capital deployment concerns. Short-term ARGX price action will reflect how the market weighs a $2.2B bet on an early-stage asset.

At the sector level, immunology and autoimmune biotech peers — particularly small/mid-caps with Phase 1 or 2 data in dermatology, GI autoimmunity, or immune modulation — may see sympathy bids as investors reprice takeout optionality. The Health Care Select Sector SPDR ETF and the broader S&P 500 healthcare weighting may see modest positive read-through. Broader indices effects are limited given the deal's mid-cap scale relative to total market cap. Volatility in FBRX should compress post-announcement as the fixed-price cash path becomes clear; ARGX implied vol may rise modestly as investors hedge pipeline and integration risk.

Start Trading on CoinUnited.io

Create Your Free Account → — Trade crypto, stocks, forex, indices, and commodities with up to 2000x leverage and zero fees.